AGIO Earnings Date: Nov 5, 2026 (Estimated) — Agios Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is AGIO's next earnings date?
Agios Pharmaceuticals, Inc. (AGIO) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.24 on revenue of $51.6M.
How did AGIO do in its last earnings report?
In its most recent report on Jul 30, 2026 (Q2 2026), Agios Pharmaceuticals, Inc. posted EPS of -$1.69 versus the -$1.71 estimate, a beat of 1.2%. Revenue was $44.7M against a $25.6M estimate. The stock's 1-day post-earnings move was -6.5%.
How much does AGIO stock move after earnings?
AGIO beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.3% (up or down) in the day after earnings.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | -1.71 | -1.69 | +1.17% | $44.7M | ✅ Beat | -6.46% | -9.40% | -2.09% |
| 2026-04-29 | Q1 2026 | -1.79 | -1.69 | +5.59% | $20.7M | ✅ Beat | +13.10% | +9.72% | +22.66% |
| 2026-02-12 | Q4 2025 | -1.96 | -1.86 | +5.10% | $20.0M | ✅ Beat | +1.30% | +3.14% | +0.51% |
| 2025-10-30 | Q3 2025 | -1.92 | -1.78 | +7.29% | $12.9M | ✅ Beat | +2.91% | -3.46% | -30.41% |
| 2025-07-31 | Q2 2025 | -1.77 | -1.93 | -9.04% | $12.5M | ❌ Miss | -0.85% | +0.48% | +1.70% |
| 2025-05-01 | Q1 2025 | -1.76 | -1.55 | +11.93% | $8.7M | ✅ Beat | +4.21% | -4.95% | +8.08% |
| 2025-02-13 | Q4 2024 | -1.63 | -1.94 | -19.02% | $10.7M | ❌ Miss | +1.49% | +2.87% | -5.73% |
| 2024-10-31 | Q3 2024 | 1.11 | -1.43 | -228.83% | $9.0M | ❌ Miss | -4.04% | +11.43% | +28.27% |
Showing last 8 quarters.